Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Autologous neuroregenerative stem cell therapy - Neuroplast

X
Drug Profile

Autologous neuroregenerative stem cell therapy - Neuroplast

Alternative Names: AMARCELL; Autologous neuro-regenerative stem cell therapy; Nepla-tem-cel - Neuroplast; Neuro-cells; Neuro-Cells®; Neuro-regenerative stem cell therapy

Latest Information Update: 11 Sep 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Neuroplast
  • Class Gene therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinal cord injuries; Frontotemporal dementia
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II/III Spinal cord injuries
  • Phase I Amyotrophic lateral sclerosis; Frontotemporal dementia; Traumatic brain injuries

Most Recent Events

  • 07 Sep 2023 Neuroplast completes enrolment in its phase-II trial for Spinal cord injuries in Spain and Denmark (Intrathecal)
  • 20 Dec 2022 Neuroplast plans market registration for Chronic spinal cord injuries before 2026 (Neuroplast website, December 2022)
  • 20 Dec 2022 Phase-I clinical trials in Amyotrophic lateral sclerosis in Netherlands (unspecified route) (Neuroplast pipeline, December 2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top